Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Targeting Tumour Cell Plasticity in Colorectal Cancer

Cel

Most cancer therapies target cell-intrinsic alterations or aim to boost immune-mediated cytotoxicity. Despite vast efforts, these strategies have not prevented or cured metastatic colorectal cancer (mCRC). A novel approach is needed. We propose to exploit a therapeutic target space revealed from the analysis of transcriptional plasticity. We will identify therapeutic drugs that treat plasticity not as a liability but as a tool to induce susceptibility. Objective 1 aims to develop a new classification of CRC based on intratumor heterogeneity (ITH): by single-cell and spatial transcriptomics, we will define common transcriptional programs and build a catalog of tumor cell state archetypes. We will then link ITH subtypes with clinical outcomes. Objective 2 searches for drugs (~2,400, mostly FDA-approved) that control plasticity: a pooled single-cell screen in PDOs representing the main ITH CRC subtypes will quantify drug-induced state shifts and nominate agents that constrain heterogeneity, generating second-hit–vulnerable states. Objective 3 will evaluate rational treatment combinations that would first reprogram composition through targeted manipulation of plasticity and then eradicate the induced vulnerable state. We will test efficacy of these novel strategies in minimal-residual-disease and overt liver metastasis preclinical CRC models. In Objective 4 we will exploit the phenotypic atlas of drug-induced reprogramming to validate mechanistic hypotheses using genetic approaches, defining key regulators of transcriptional plasticity. Together, we will establish a precision-oncology paradigm centered on targeting plasticity for mCRC. We expect to deliver at least one proof of principle therapeutic strategy tailored to each ITH CRC subtype, exploiting rational drug sequences that leverage plasticity as a vulnerability. Because our screening library emphasizes repurposable drugs, prioritized combinations will be well positioned for medium term clinical evaluation.

Dziedzina nauki (EuroSciVoc)

Słowa kluczowe

Program(-y)

Temat(-y)

System finansowania

HORIZON-ERC - HORIZON ERC Grants

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) ERC-2025-ADG

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Instytucja przyjmująca

FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)
Wkład UE netto
€ 2 499 887,00
Koszt całkowity
Brak danych

Beneficjenci (1)